Citalopram: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
===Citalopram 20mg=== | ===Citalopram 20mg=== | ||
[[File:Citalopram 20mg.mp3]] | [[File:Citalopram 20mg.mp3]] | ||
==Common Strengths of Citalopram Tablet== | |||
Citalopram are available in the following strengths: | |||
*Tablets: 10 mg, 20 mg, 40 mg | |||
*Oral solution: 10 mg/5 mL | |||
==Drug Trade Names of Citalopram Tablet== | |||
CIPRAM | |||
==Drug Usage== | |||
*Major depressive disorder (MDD) in adults | |||
*Off-label uses: Generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder, premenstrual dysphoric disorder (PMDD) | |||
==Mechanism of Action== | |||
It works by increasing serotonin levels in the brain by inhibiting its reuptake into presynaptic neurons, thereby enhancing serotonergic activity. | |||
==Route of Administration== | |||
Oral (tablets and solution) | |||
==Dosages== | |||
*Initial dose: 20 mg once daily | |||
*Maintenance dose: 20 - 40 mg once daily | |||
*Maximum dose: 40 mg/day | |||
*Elderly: Recommended dose is 20 mg/day | |||
==Side Effects== | |||
{| class="wikitable" | |||
!style="text-align: left"| Frequency | |||
!Adverse reactions | |||
|- | |||
| rowspan="12" | '''Common | |||
| Nausea | |||
|- | |||
| Dry mouth | |||
|- | |||
| Increased sweating | |||
|- | |||
| Drowsiness | |||
|- | |||
| Insomnia | |||
|- | |||
| Dizziness | |||
|- | |||
| Fatigue | |||
|- | |||
| Weakness | |||
|- | |||
| Tremor (shaking) | |||
|- | |||
| Sexual dysfunction (e.g. decreased libido, difficulty achieving orgasm, erectile dysfunction) | |||
|- | |||
| Diarrhea or constipation | |||
|- | |||
| Loss of appetite | |||
|- | |||
| rowspan="9" | '''Serious | |||
| Allergic reactions: Symptoms such as hives, difficulty breathing, and swelling of the face, lips, tongue, or throat | |||
|- | |||
| Serotonin syndrome: Symptoms include agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea | |||
|- | |||
| QT prolongation: A dangerous heart rhythm condition that can lead to torsades de pointes. Symptoms may include fainting, dizziness, or irregular heartbeat | |||
|- | |||
| Suicidal thoughts or behaviors: Particularly in young adults, teenagers, and children, especially when starting the medication or adjusting the dose | |||
|- | |||
| Manic episodes: Symptoms include racing thoughts, increased energy, decreased need for sleep, risk-taking behavior, and being unusually talkative or agitated | |||
|- | |||
| Severe nervous system reactions: Symptoms include very stiff muscles, high fever, sweating, confusion, fast or uneven heartbeats, and tremors | |||
|- | |||
| Unusual bleeding: Including nosebleeds, bleeding gums, abnormal vaginal bleeding, or any bleeding that does not stop | |||
|- | |||
| Low blood sodium (hyponatremia): Symptoms include headache, confusion, problems with thinking or memory, weakness, and feeling unsteady | |||
|- | |||
| Seizures | |||
|} | |||
==Pharmacokinetics== | |||
*Peak plasma level is approximately 4 hours after oral dosing | |||
*Metabolism: Citalopram is primarily metabolized in the liver by CYP3A4 and CYP2C19. | |||
*Elimination: Half-life is about 35 hours. Approximately 12-23% of an oral dose is excreted unchanged in urine and about 10% is excreted in feces. | |||
These pharmacokinetic properties contribute to citalopram's once-daily dosing regimen. | |||
Onset Time and Duration of drug action | |||
*Onset: Therapeutic effects typically observed within 1-4 weeks. | |||
*Duration: Steady-state achieved within 1 week. | |||
==Drug Precautions== | |||
'''Pregnancy | |||
May cause complications such as persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation if used in the third trimester. | |||
'''Breastfeeding | |||
Use with caution; citalopram is excreted in human milk. | |||
'''Children and Elderly | |||
*Children: Safety and effectiveness not established in pediatric patients | |||
*Elderly: Recommended dose is 20 mg/day due to increased sensitivity | |||
'''Renal Impairment | |||
No dosage adjustment necessary for mild-to-moderate impairment; use with caution in severe impairment | |||
'''Monitoring Requirements | |||
Citalopram, a selective serotonin reuptake inhibitor (SSRI), requires careful monitoring and management to ensure patient safety and therapeutic efficacy. Here are the key aspects of moritoring and management: | |||
Before Treatment | |||
*Electrolytes: | |||
**Monitor and evaluate baseline levels of potassium and sodium | |||
**Correct any hypokalemia or hypomagnesemia before starting treatment | |||
**Periodically re-evaluate electrolytes, especially in patients at riks for electrolyte disturbances | |||
*ECG Monitoring: | |||
**Perform an ECG to check for QT prolongation in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. | |||
**Avoid citalopram or use with caution in patients taking other QT-prolonging drugs | |||
Drug Treatment | |||
*Mental Health Monitoring: | |||
**Assess and monitor for worsening depression, suicidality, or unusual changes in behavior, particularly during the initial few months of therapy or when adjusting doses | |||
**Weekly face-to-face contact is recommended during the first month, followed by bi-weekly visits for the next month, and then at 3-month intervals | |||
*Weight and Growth: | |||
**Regularly monitor weight and growth in children and adolescents undergoing treatment | |||
*Psychiatric Assessment: | |||
**Use standardized scales to screen for anxiety and depression and to monitor response to therapy, such as: | |||
**Patient Health Questionnaire (PHQ-9) | |||
**Generalized Anxiety Disorder 7 score (GAD-7) | |||
**Hamilton Anxiety Scale (HAM-A) | |||
*Toxicity and Overdose Management | |||
**Serotonin Syndrome | |||
***Be vigilant for signs of serotonin syndrome, especially if the patient is on other serotonergic medications. | |||
***Symptoms include agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea | |||
**Patient Education | |||
***Educate patients about the risks of combining citalopram with alcohol, sedatives, and other antidepressants | |||
*Special Considerations: | |||
**Elderly Patients: | |||
***The maximum recommended dose for patients older than 60 years is 20 mg per day due to increased risk of QT prolongation | |||
***Monitor for persistent QTc measurements greater than 500 ms and discontinue citalopram if necessary | |||
**Monitor for abnormal bleeding | |||
'''Drug Interactions | |||
Major Drug interactions | |||
*Serotonergic Drugs | |||
**Drugs: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, St. John's Wort | |||
**Risk: Increased risk of serotonin syndrome | |||
**Management: | |||
***Monitor for signs and symptoms of serotonin syndrome, especially during initiation or dose changes | |||
*QT-Prolonging Medications | |||
**Risk: Increased risk of QT prolongation and life-threatening arrhythmias | |||
**Management: | |||
***Perform ECG before starting treatment, especially in high-risk patients | |||
***Avoid combination if possible, or use with caution and close monitoring | |||
***Monitor electrolytes, particularly potassium and magnesium | |||
*Anticoagulants and Antiplatelet Agents** | |||
**Risk: Increased risk of bleeding | |||
**Management: | |||
***Inform patients of increased bleeding risk | |||
***Monitor closely, especially INR for patients on warfarin | |||
*Other Significant Interactions | |||
**NSAIDs: May increase bleeding risk; use with caution | |||
**CYP2C19 inhibitors: May increase citalopram levels; dose adjustment may be necessary | |||
==FAQ== | |||
'''How Should I Take the Tablet? | |||
Take once daily, with or without food. | |||
'''What Should I Avoid While Taking? | |||
Avoid alcohol and activities requiring mental alertness until you know how trifluoperazine affects you. | |||
'''What Happens if I Miss a Dose? | |||
Take the missed dose as soon as you remember unless it is almost time for your next dose. Do not double doses. | |||
Latest revision as of 01:57, 1 August 2024
Drug class: Selective Serotonin Reuptake Inhibitor
Citalopram (CIPRAM)(中文:西酞普蘭)
Pronunciation[edit]
Citalopram 20mg[edit]
Common Strengths of Citalopram Tablet[edit]
Citalopram are available in the following strengths:
- Tablets: 10 mg, 20 mg, 40 mg
- Oral solution: 10 mg/5 mL
Drug Trade Names of Citalopram Tablet[edit]
CIPRAM
Drug Usage[edit]
- Major depressive disorder (MDD) in adults
- Off-label uses: Generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder, premenstrual dysphoric disorder (PMDD)
Mechanism of Action[edit]
It works by increasing serotonin levels in the brain by inhibiting its reuptake into presynaptic neurons, thereby enhancing serotonergic activity.
Route of Administration[edit]
Oral (tablets and solution)
Dosages[edit]
- Initial dose: 20 mg once daily
- Maintenance dose: 20 - 40 mg once daily
- Maximum dose: 40 mg/day
- Elderly: Recommended dose is 20 mg/day
Side Effects[edit]
| Frequency | Adverse reactions |
|---|---|
| Common | Nausea |
| Dry mouth | |
| Increased sweating | |
| Drowsiness | |
| Insomnia | |
| Dizziness | |
| Fatigue | |
| Weakness | |
| Tremor (shaking) | |
| Sexual dysfunction (e.g. decreased libido, difficulty achieving orgasm, erectile dysfunction) | |
| Diarrhea or constipation | |
| Loss of appetite | |
| Serious | Allergic reactions: Symptoms such as hives, difficulty breathing, and swelling of the face, lips, tongue, or throat |
| Serotonin syndrome: Symptoms include agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea | |
| QT prolongation: A dangerous heart rhythm condition that can lead to torsades de pointes. Symptoms may include fainting, dizziness, or irregular heartbeat | |
| Suicidal thoughts or behaviors: Particularly in young adults, teenagers, and children, especially when starting the medication or adjusting the dose | |
| Manic episodes: Symptoms include racing thoughts, increased energy, decreased need for sleep, risk-taking behavior, and being unusually talkative or agitated | |
| Severe nervous system reactions: Symptoms include very stiff muscles, high fever, sweating, confusion, fast or uneven heartbeats, and tremors | |
| Unusual bleeding: Including nosebleeds, bleeding gums, abnormal vaginal bleeding, or any bleeding that does not stop | |
| Low blood sodium (hyponatremia): Symptoms include headache, confusion, problems with thinking or memory, weakness, and feeling unsteady | |
| Seizures |
Pharmacokinetics[edit]
- Peak plasma level is approximately 4 hours after oral dosing
- Metabolism: Citalopram is primarily metabolized in the liver by CYP3A4 and CYP2C19.
- Elimination: Half-life is about 35 hours. Approximately 12-23% of an oral dose is excreted unchanged in urine and about 10% is excreted in feces.
These pharmacokinetic properties contribute to citalopram's once-daily dosing regimen.
Onset Time and Duration of drug action
- Onset: Therapeutic effects typically observed within 1-4 weeks.
- Duration: Steady-state achieved within 1 week.
Drug Precautions[edit]
Pregnancy
May cause complications such as persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation if used in the third trimester.
Breastfeeding
Use with caution; citalopram is excreted in human milk.
Children and Elderly
- Children: Safety and effectiveness not established in pediatric patients
- Elderly: Recommended dose is 20 mg/day due to increased sensitivity
Renal Impairment
No dosage adjustment necessary for mild-to-moderate impairment; use with caution in severe impairment
Monitoring Requirements
Citalopram, a selective serotonin reuptake inhibitor (SSRI), requires careful monitoring and management to ensure patient safety and therapeutic efficacy. Here are the key aspects of moritoring and management:
Before Treatment
- Electrolytes:
- Monitor and evaluate baseline levels of potassium and sodium
- Correct any hypokalemia or hypomagnesemia before starting treatment
- Periodically re-evaluate electrolytes, especially in patients at riks for electrolyte disturbances
- ECG Monitoring:
- Perform an ECG to check for QT prolongation in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.
- Avoid citalopram or use with caution in patients taking other QT-prolonging drugs
Drug Treatment
- Mental Health Monitoring:
- Assess and monitor for worsening depression, suicidality, or unusual changes in behavior, particularly during the initial few months of therapy or when adjusting doses
- Weekly face-to-face contact is recommended during the first month, followed by bi-weekly visits for the next month, and then at 3-month intervals
- Weight and Growth:
- Regularly monitor weight and growth in children and adolescents undergoing treatment
- Psychiatric Assessment:
- Use standardized scales to screen for anxiety and depression and to monitor response to therapy, such as:
- Patient Health Questionnaire (PHQ-9)
- Generalized Anxiety Disorder 7 score (GAD-7)
- Hamilton Anxiety Scale (HAM-A)
- Toxicity and Overdose Management
- Serotonin Syndrome
- Be vigilant for signs of serotonin syndrome, especially if the patient is on other serotonergic medications.
- Symptoms include agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea
- Patient Education
- Educate patients about the risks of combining citalopram with alcohol, sedatives, and other antidepressants
- Serotonin Syndrome
- Special Considerations:
- Elderly Patients:
- The maximum recommended dose for patients older than 60 years is 20 mg per day due to increased risk of QT prolongation
- Monitor for persistent QTc measurements greater than 500 ms and discontinue citalopram if necessary
- Monitor for abnormal bleeding
- Elderly Patients:
Drug Interactions
Major Drug interactions
- Serotonergic Drugs
- Drugs: Other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, St. John's Wort
- Risk: Increased risk of serotonin syndrome
- Management:
- Monitor for signs and symptoms of serotonin syndrome, especially during initiation or dose changes
- QT-Prolonging Medications
- Risk: Increased risk of QT prolongation and life-threatening arrhythmias
- Management:
- Perform ECG before starting treatment, especially in high-risk patients
- Avoid combination if possible, or use with caution and close monitoring
- Monitor electrolytes, particularly potassium and magnesium
- Anticoagulants and Antiplatelet Agents**
- Risk: Increased risk of bleeding
- Management:
- Inform patients of increased bleeding risk
- Monitor closely, especially INR for patients on warfarin
- Other Significant Interactions
- NSAIDs: May increase bleeding risk; use with caution
- CYP2C19 inhibitors: May increase citalopram levels; dose adjustment may be necessary
FAQ[edit]
How Should I Take the Tablet?
Take once daily, with or without food.
What Should I Avoid While Taking?
Avoid alcohol and activities requiring mental alertness until you know how trifluoperazine affects you.
What Happens if I Miss a Dose?
Take the missed dose as soon as you remember unless it is almost time for your next dose. Do not double doses.
